08.08.2011 • News

Arch Chemicals Q2 Profit Falls

Biocides company Arch Chemicals, which is in $1.4 billion cash deal to be acquired by Lonza reported that its second-quarter earnings from continuing operations was $37.4 million or $1.47 per share, lower than prior year's $43.5 million or $1.73 per share.

The latest quarter results included a charge of $0.3 million or $0.01 per share, for relocation costs incurred in conjunction with the previously announced research and development consolidation.

Excluding this item, earnings from continuing operations for 2011 were $37.7 million or $1.48 per share.

Analysts polled by Thomson Reuters expected earnings of $1.82 per share for the quarter. Analysts' estimates typically exclude special items.
The company noted that the second-quarter earnings were significantly impacted by lower-than-expected results from the HTH water products business, principally due to timing.

Sales for the second quarter were $443.8 million, compared to $441.4 million for the second quarter of 2010.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

most read